Windlass Biotech IPO: Refund status, share transfer to demat account, direct links to check allotment and listing updates

Windlass Biotech IPO: Refund status, share transfer to demat account, direct links to check allotment and listing updates

[ad_1]

Windlass Biotech IPO closed on August 6, 2021, with the issue getting subscribed 22.46 times on the last day. The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data.  The initial public offer had a fresh issue of up to Rs 165 crore and an offer for sale of up to 51,42,067 equity shares. The Rs 401.53-crore offer had a price range of Rs 448-460 per share. 

See Zee Business Live TV Streaming Below:

As per brokerage firm Edelweiss, Windlas Biotech IPO’s refund initiation process is likely on August 13, 2021.  The transfer of shares into the demat accounts is expected August 16, while the listing of stock is expected to be on 17 August, as per Edelweiss.  

Those who have applied for this issue and haven’t checked their allotment status of this issue yet can do it via BSE and Link Intime, the registrar of the issue, websites.   

Windlass Biotech IPO allotment status check via BSE Website-     

Step 1: Visit the link: bseindia.com/investors/appli_check.aspx on BSE official website.     

Step 2:  In the dropdown menu select ‘Equity’ for issue type. 

Step 3: Select the name of the IPO. 

Step 4: You will be asked to verify application number & PAN number. 

Step 5: Hit search button and you are good to go. You can see your IPO allotment on the screen. 

Steps to check allotment status via Link Intime: 

Step1: Visit Link Intime India Private Limited IPO allotment link: https://linkintime.co.in/MIPO/Ipoallotment.html

Step 2: Select IPO Name. 

Step 3: Fill in details such as PAN number, application number or DP ID. 

Step 4: Click on ‘Search’ Button. 

The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capital requirements, repayment/ prepayment of certain borrowings, and general corporate purposes. 

 



[ad_2]

Source link

Share

Leave a Reply

Your email address will not be published. Required fields are marked *

Share This